Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

Publications

HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis.

Alderuccio JP. et al, (2021), Blood Adv, 5, 2852 - 2862

A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma.

Booth SW. et al, (2021), BMC Cancer, 21

The tumor microenvironment and immune responses in prostate cancer patients.

Kwon JTW. et al, (2021), Endocr Relat Cancer, 28, T95 - T107

Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021.

Mughal TI. et al, (2021), Haematologica, 106, 1787 - 1793

Phase I, first-in-human trial evaluating BI 1387446 (STING agonist) alone and in combination with ezabenlimab (BI 754091; anti-PD-1) in solid tumors.

Harrington K. et al, (2021), CANCER RESEARCH, 81

Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort.

Martinez-Calle N. et al, (2021), Adv Ther, 38, 3789 - 3802

The clinical and molecular significance associated with STING signaling in breast cancer.

Parkes EE. et al, (2021), NPJ Breast Cancer, 7

Familial thrombocytopenia: The long and short of it.

Murphy L. and Mead AJ., (2021), J Exp Med, 218

A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer.

Kazmi F. et al, (2021), Clin Cancer Res, 27, 3028 - 3038

BEYOND A BINARY ENDPOINT: LONGITUDINAL AND INDIVIDUAL SYMPTOM ANALYSES FROM THE SIMPLIFY-1 STUDY DEMONSTRATE CLINICALLY COMPARABLE SYMPTOMATIC BENEFIT OF MOMELOTINIB TO RUXOLITINIB IN JAK INHIBITOR NAIVE MYELOFIBROSIS PATIENTS

Mesa R. et al, (2021), VALUE IN HEALTH, 24, S22 - S22

Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study.

Hamadani M. et al, (2021), Lancet Haematol, 8, e433 - e445

Development of Immunotherapy Combination Strategies in Cancer.

Yap TA. et al, (2021), Cancer Discov, 11, 1368 - 1397

Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial.

Hall PS. et al, (2021), JAMA Oncol, 7, 869 - 877

Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAs) with stage III or IV Hodgkin lymphoma: A subgroup analysis from the phase 3 Echelon-1 study.

Crosswell HE. et al, (2021), JOURNAL OF CLINICAL ONCOLOGY, 39

Longitudinal and individual symptom analyses of momelotinib and ruxolitinib treated myelofibrosis patients from SIMPLIFY-1.

Mesa RA. et al, (2021), JOURNAL OF CLINICAL ONCOLOGY, 39

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

Ahern DJ. et al, (2021)

Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor initiating cells

Masuda K. et al, (2021), JCI Insight

Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles.

Ye W. et al, (2021), Br J Cancer, 124, 1661 - 1669

Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis.

Li J. et al, (2021), Cancer Discov, 11, 1212 - 1227

Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP.

Eyre TA. et al, (2021), Blood Adv, 5, 2229 - 2236